The Pharmaceutical Research Shared Resource, consisting of an Investigational Chemotherapy Service and a Cancer Clinical Pharmacology Laboratory, provides a broad range of services to support the conduct of clinical hematology/oncology research. The Investigafional Chemotherapy Service (ICS) is available to all Duke Cancer Institute investigators for the purpose of maintaining drug accountability records and investigafional drug Inventories according to FDA and CTEP guidelines. In addition, this resource provides design consultafion, professional staff educafion, and implementafion services for clinical research studies. The primary focus ofthe Clinical Pharmacology Lab (GPL) is to invesfigate the pharmacokinefics and pharmacodynamics of anticancer drugs and recombinant proteins used in the experimental therapy of cancer. This resource is also available for analysis of endogenous cytokine concentrations during investigational therapy. One of the major goals of the laboratory is to identify predictors of resppnse and toxicity and implement methods to reduce inter-patient variability and drug exposure. The lab provides both consultative and analytic services regarding clinical pharmacokinetic studies of anticancer compounds and recombinant proteins. These include: aid with trial design, opfimal sampling techniques, sample handling and stability, quantitative measurement of drug and metabolite concentrafions (via HPLC, atomic absorpfion spectrophotometry, gas chromatography/mass spectrophotometry, or ELISA), calculation of individual and populafion pharmacokinetic parameters and pharmacometric evaluafion via sophisficated computer modeling programs. This resource has maintained a high level of usage by Duke Cancer Institute investigators including those from the Experimental Therapeutics Program, Breast arid Ovarian Oncology, Hematopoietic Transplantafion and Hematologic Malignancies, Neuro-Oncology, Radiation, and Cancer Biology Programs.

Public Health Relevance


National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
McDonnell, Eoin; Crown, Scott B; Fox, Douglas B et al. (2016) Lipids Reprogram Metabolism to Become a Major Carbon Source for Histone Acetylation. Cell Rep 17:1463-1472
Liu, Hongliang; Gao, Fengqin; Dahlstrom, Kristina R et al. (2016) A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck. Tumour Biol 37:8057-66
Evans, M K; Sauer, S J; Nath, S et al. (2016) X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis 7:e2073
Pollock, Julie A; Wardell, Suzanne E; Parent, Alexander A et al. (2016) Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. Nat Chem Biol 12:795-801
He, Kevin; Li, Yanming; Zhu, Ji et al. (2016) Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates. Bioinformatics 32:50-7
Yuan, Hua; Liu, Hongliang; Liu, Zhensheng et al. (2016) A Novel Genetic Variant in Long Non-coding RNA Gene NEXN-AS1 is Associated with Risk of Lung Cancer. Sci Rep 6:34234
Schaal, Jeffrey L; Li, Xinghai; Mastria, Eric et al. (2016) Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy. J Control Release 228:58-66
Pilaz, Louis-Jan; Lennox, Ashley L; Rouanet, Jeremy P et al. (2016) Dynamic mRNA Transport and Local Translation in Radial Glial Progenitors of the Developing Brain. Curr Biol 26:3383-3392
Matak, Pavle; Matak, Andrija; Moustafa, Sarah et al. (2016) Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Proc Natl Acad Sci U S A 113:3428-35
Friedman, Daphne R; Sibley, Alexander B; Owzar, Kouros et al. (2016) Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. Am J Hematol 91:687-91

Showing the most recent 10 out of 443 publications